{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.505","upperLimit":"0.779","value":"0.652"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"MRD negative response after ASCT is defined as achievement of MRD negative status in the bone marrow by flow cytometry (multiparameter flow cytometry \\[MPF\\]) at the day 100 post ASCT visit. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. 95 percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, and on days 1 and 15 of cycles 3-4. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after completion of daratumumab cycle 2 or 4, patients undergo ASCT. Within 14 days after completion of day 100 visit post-SCT, patients receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Daratumumab, ASCT, Lenalidomide)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days","title":"Rate of Minimal Residual Disease (MRD) Negative Response After Autologous Stem Cell Transplantation (ASCT)","type":"PRIMARY","unitOfMeasure":"proportion of participants"}